Anti-PL-7 antisynthetase syndrome presenting as COVID-19

Abstract

DEAR EDITOR, Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clusters were first identified in December 2019 in Wuhan, China; subsequently, rapid spread has resulted in an ongoing pandemic. We present the case of a 72-year-old man who attended the Emergency Department during the first peak of the UK epidemic with a 3-week history of unexplained flu-like symptoms. The patient reported fever, non-drenching sweats, dry cough, arthralgia, myalgia, bilateral pleuritic chest pains, shortness of breath and unremitting fatigue. His past medical history comprised mild chronic obstructive pulmonary disease, OA and hyperlipidaemia, for which he was taking Simvastatin, Losartan, Omeprazole, a combination inhaler containing fluticasone furoate/umeclidinium/vilanterol, diclofenac 1.16% gel and co-codamol 15/500. He denied any weight loss. He was an exsmoker. Initial observations demonstrated peripheral oxygen saturation 89% in room air, respiratory rate 36 breaths/min, blood pressure 112/73 mmHg, heart rate 121 beats per min and temperature 38.0 C. No further fevers were documented throughout his admission. Skin and mucous membranes were unremarkable. Bedside digital assessment revealed abnormal nailfold changes typical of nailfold infarcts to the left ring and little fingers, and two splinter haemorrhages to the left index finger. Extremities were well perfused with capillary refill time <2 seconds. No Osler nodes or Janeway lesions were identified. On cardiorespiratory assessment, he was found to be euvolaemic with no jugular venous distension, an undisplaced apex beat, normal heart sounds and bibasal end-inspiratory crackles. There was no demonstrable synovitis. Muscle power was 4þ/5 in proximal muscle groups using the Medical Research Council grading scale. A working diagnosis of COVID-19 was made prior to investigations. Blood tests revealed: urea 9.8 mmol/l (2.5–7.8), creatinine 77mmol/l (65–105), albumin 28 g/l (35–50), alanine aminotransferase 36 U/l (10–50), ALP 274 U/l (40–130), adjusted calcium 2.25 mmol/l (2.10–2.58), haemoglobin 130 g/l (130–170), white blood cells 20.77 10 (4.00– 11.00), neutrophils 18.11 10 (2.00–7.00), lymphocytes 1.41 10 (1.00–3.00), monocytes 0.77 10 (0.20– 1.00), platelets 391 10 (140–400), CRP 143 mg/l (<11), ESR 44 mm/h, ferritin 592 lg/l (15–350), troponin T 115 ng/l, procalcitonin 0.14 ug/l (< 0.06) and brain natriuretic peptide (NT-pro BNP) 109 pmol/l (<42). Immunology was negative for ANA, ANCA, anti-dsDNA antibodies, PR3, MPO, cardiolipin IgG, IgM and beta-2glycoprotein-1 antibodies, and original C3 was 1.24 g/l (0.75–1.75) and C4 0.20 g/l (0.14–0.54). Creatine kinase (CK), checked 1 week into the hospital episode (5 days after starting steroids), was 491 U/l (30–175). SARS-Cov2 RNA 4 was not detected by RT-PCR, three sets of blood cultures showed no growth, HIV, HBV and HBC serology were negative, and Legionella urinary antigen was not detected. Urinalysis by dipstick and microscopy was unremarkable. Chest radiogram showed bilateral, mainly left lower lobe, areas of opacification, as well as minor right and mild left pleural effusions, the findings of which were thought to represent infection. The patient was treated with ward-based oxygen, i.v. antibiotics and diuretics, later followed by prednisolone 30mg daily; however, he failed to improve and developed worsening digital vasculitis with necrotic fingertips and respiratory compromise (Fig. 1A and B). High-resolution CT depicted bilateral subpleural consolidation and developing fibrosis within the areas of consolidation, which raised the possibility of organizing pneumonia (Fig. 1C). On day 8, the patient underwent a trans-oesophageal echocardiogram, which confirmed normal biventricular size and systolic function, no significant valve dysfunction and no echocardiographic features of endocarditis. Twelve days into admission, myositis-specific antibody screening confirmed the presence of anti-PL-7 antibodies. Consequently, the patient received urgent treatment with i.v. methylprednisolone and CYC 10 mg/kg (2-weekly for first three, then 3-weekly for six), in conjunction with mesna, co-trimoxazole and nystatin. He was also given aspirin 75 mg daily, HCQ 200 mg daily, prednisolone reducing regime and sildenafil 25 mg three times daily. After 3 months, the patient had made a rapid recovery, with no further symptoms, and repeat high-resolution CT showed near-complete resolution of earlier changes. Myalgia, fatigue and weakness are frequently encountered with viral pathogens, not least with the coronavirus family. The Lancet published a report of 41 patients hospitalized with pneumonia: 33% of them showed CK elevation and that number increased up to 46% in intensive care unit patients [1]. Antisynthetase syndrome (ASS) is a rare autoimmune disease characterized by interstitial lung disease (ILD) and/or inflammatory myositis, with positive antisynthetase antibodies (anti-Jo-1, anti-PL-7, anti-PL-12, anti-ZO, anti-OJ, anti-KE or anti-KS). Rheumatology key message